肠道菌群影响免疫检查点抑制剂治疗癌症的研究进展

摘要

人体肠道内寄生着约1014个共生菌群,这些菌群可以帮助分解人体内的食物,其代谢产物能影响人体消化能力、抗自身免疫性疾病的能力等,是人体内不可忽视的重要"器官".最近的研究发现,人体内的肠道菌群可以影响免疫检查点抑制剂(Immune-checkpoint blockers,ICB)治疗癌症.本文将结合近几年的研究成果,对癌症免疫治疗后出现的不良反应、肠道菌群及肠道菌群如何影响免疫检查点抑制剂(ICB)治疗癌症的研究进展进行总结,最后对肠道菌群影响癌症治疗进行展望,以期能够为研究肠道菌群与癌症治疗的关系提供理论依据.%Numbers of commensal microbiota live in the human intestine.Intestinal flora can help their host digest food and their metabolite can affect human′s capacity of digestion.In addition,commensal microbiota can improve the ability of host against auto-immune disease and so on.Therefore,the commensal microbiota may be regarded as an essential"organ" in our body.Recent research has revealed that gut microbiota can affect the cancer immunotherapy upon immune-checkpoint blockers(ICB).Combined with recent study results,this article reviews the immune-related adverse events after cancer immunotherapy,introduction of gut microbiota and research progress on impact of gut microbiota on cancer immunotherapy upon immune-checkpoint blockers.In addition,there is an outlook for the future research on gut microbiota against cancer.This article will provide a theoretical reference for study of the relationship of gut microbiota and cancer treatment.